Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus
https://doi.org/10.31146/1682-8658-ecg-214-6-121-129
Abstract
Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2) often coexist and share common pathogenic mechanisms& Being components of the metabolic syndrome, these pathologic conditions exacerbate each other’s course, increase the risk of adverse cardiovascular outcomes in comorbid patients. The main focus in the treatment of patients with DM2 and NAFLD is aimed at reducing insulin resistance and slowing down the transition of steatosis and/or steatohepatitis into a more progressive stage. For this aim, a number of hypoglycemic drugs are used in diabetology, which have demonstrated their beneficial effects on the NAFLD. This article presents the results of clinical and experimental studies on the use of the following groups of drugs in patients with NAFLD: biguanides, glucagon-like peptide-1 agonists, type 4 dipeptidylpeptidase inhibitors, thiazolidindiones and type 2 glucoze-sodium transporter inhibitors. The most promising in the treatment of patients with type 2 diabetes and NAFLD are pioglitazone, liraglutide and dapagliflozin.
About the Authors
E. V. Uzhakova
Perm State Medical University n. a. E. A. Wagner of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Z. E. Zshanko
Perm State Medical University n. a. E. A. Wagner of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. N. Smirnova
Perm State Medical University n. a. E. A. Wagner of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Lazebnik L. B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 185(1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.
2. Younossi Z., Anstee Q. M., Marietti M., et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. and Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109.
3. Belenkov Y. N., Privalova E. V., Kaplunova V. Y., Zektser V. Y., Vinogradova N. N., Ilgisonis I. S., Shakaryants G. A., Kozhevnikova M. V., Lishuta A. S. Metabolic Syndrome: Development of the Issue, Main Diagnostic Criteria. Rational Pharmacotherapy in Cardiology. 2018; 14(5):757-764. (In Russ.) doi: 10.20996/1819-6446-2018-14-5-757-764.@@ Беленков Ю. Н., Привалова Е. В., Каплунова В. Ю. и соавт. Метаболический синдром: история развития, основные критерии диагностики. Рациональная фармакотерапия в кардиологии. 2018. Е.14. № 5. С. 757-765.
4. Shulkina S. G., Erbes P. E., Smirnov E. N. The contribution of the polymorphism of MMR 12 (rs652483) and PPARG (rs1801282) genes to the formation of NAFLD in obese patients. Terapy. 2022;10 (62):79-88. (in Russ.) doi: 10.18565/therapy.2022.10.79-88.@@ Шулькина С. Г., Эрбес П. Э., Смирнова Е. Н. Значение полиморфизма генов ММР 12 (RS652483) и PPARG (RS 1801282) в формировании неалкогольной жировой болезни печени у женщин с ожирением. Терапия. 2022. Т. 8. № 10 (62). С. 79-88.
5. Lonardo A., Ballestri S., Marchesini G, et al. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig Liver Dis. 2015;47(3):181-190. doi. 101016/j.dld.2014.09.020.
6. Targher G., Corey K. E., Byrne C. D., Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat. Rev. Gastroenterol Hepatol. 2021;18(9):599-612. doi:10.1038/s41575-021-00448-y.
7. Lee B. W., Lee Y. H., Park C. Y.; Korean Diabetes Association (KDA) Fatty Liver Research Group. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab J. 2020 Jun;44(3):382-401. doi: 10.4093/dmj.2020.0010.
8. Jarvis H., Craig D., Barker R. et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systemic review and meta-analysis of population -based observational studies. PLoS Med. 2020. 30 17(4): e1003100. doi:10.1371/journal.pmed.1003100.
9. Eslam M., Sanyal A. J., George J.; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312.
10. Eslam M., Newsome P. N., Sarin S. K., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039.
11. Younossi Z. M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431.
12. Korneeva O. N., Drapkina O. M., Bueverov A. O. Non-alcoholic fatty liver disease as a manifestation of the metabolic syndrome. Clinical perspectives of gastroenterology, hepatology. 2005;(4):21-25. (in Russ.)@@ Корнеева О. Н., Драпкина О. М., Буеверов А. О. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клинические перспективы гастроэнтерологии, гепатологии. 2005;(4):21-25.
13. Makarov I. O., Borovkova E. I., Kazakov R. D. Prevalence of non-alcoholic fatty liver disease in obese pregnant women. Obstetrics. Gynecology. Reproduction. 2012;6(4): 18. (in Russ.)@@ Макаров И. О., Боровкова Е. И., Казаков Р. Д. Распространенность неалкогольной жировой болезни печени у беременных с ожирением. Акушерство. Гинекология. Репродукция. 2012. Т. 6, N 4, С. 18.
14. Younossi Z. M., Golabi P., de Aliva L., et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol.2019; 71(4):793-801. doi: 10.1016/j.jhep2019.0.
15. Dongiovanni P., Stender S., Pietrelli A., et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719.
16. Bakulin I. G., Sandler Yu.G., Vinnitskaia E. V., Keyan V. A., Rodionova S. V., Rotin D. L. Diabetes mellitus and nonalcoholic fatty liver disease: The verges of contingency. Terapevticheskii Arkhiv. 2017;89(2):59-65. (In Russ.) doi: 10.17116/terarkh201789259-65.@@ Бакулин И. Г., Сандлер Ю. Г., Винницкая Е. В. и др. Сахарный диабет и неалкогольная жировая болезнь печени: грани сопряженности. Терапевтический архив. -2017. Т. 89. -№ 2. -С.59-65. doi: 10.17116/terarkh201789259-65.
17. Galsgaard K. D. The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. J Clin Med. 2020 Dec 15;9(12):4049. doi: 10.3390/jcm9124049.
18. Godoy-Matos A.F., Silva Júnior W. S., Valerio C. M. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020 Jul 14;12:60. doi: 10.1186/s13098-020-00570-y.
19. Drapkina O. M., Ivashkin V. T. Epidemiological features of non-alcoholic fatty liver disease in Russia (results of an open multicenter prospective observational study DIREG 01903).Russian journal of gastroenterology, hepatology, coloproctology. 2014;24(4):32-8. (in Russ.)@@ Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования-наблюдения DIREG 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(4):32-8.
20. Jun Chen, Piao Hu, Yanfei Wang and Zhongxin Zhu. Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ³
Review
For citations:
Uzhakova E.V., Zshanko Z.E., Smirnova E.N. Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus. Experimental and Clinical Gastroenterology. 2023;(6):121-129. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-214-6-121-129
Views:
333
Email this article 